Hormonal
GLP1:Gcg dual agonists (Mazdutide and Cotadutide) show promise in weight loss and glycemic control, with additional benefits for Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH).
GLP1:Gcg dual agonists like Mazdutide and Cotadutide show significant weight loss and glycemic benefits, with additional advantages for liver health in NAFLD/NASH patients. Mazdutide showed 11.7% weight loss in 12 weeks, while Cotadutide showed weight loss comparable to Liraglutide over 54 weeks. These therapies are promising but still under investigation.
Beyond body weight loss and improved glycemic control, the GLP1:Gcg dual agonists have also been assessed for their efficacy in patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH).
Why this rating
Based on Phase II trials and some Phase Ib data, indicating promising but not yet fully established clinical data.
Source
Designer GLP1 poly-agonist peptides in the management of diabesity
Laura Statham et al. · Expert Review of Endocrinology & Metabolism · 2023
DOI 10.1080/17446651.2023.2204976
More from this paper
- Tirzepatide, a GLP1:GIP dual agonist, provides superior glycemic and weight-loss efficacy compared to placebo, achieving >20% body weight loss in 57% of participants at the highest dose over 72 weeks.Good
- GLP1:GIP:Gcg triple agonists (SAR441255) show potential for weight loss and neurological benefits, including improved memory in mouse models of TBI and Alzheimer's disease.Limited
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →